Gonadorelin dosage: reported doses and schedule
A short-acting fertility hormone used in tests and specialist pump therapy.
Also called: GnRH, LHRH, gonadorelin acetate, gonadorelin hydrochloride, Factrel, Lutrepulse.
Reproductive axis peptides · Gonadotropin-releasing hormone receptor agonist · Evidence: Approved drug.
Typical reported dose: 200 mcg every 3.5 days (twice a week)
- Pituitary response test: SC: 100 mcg once single diagnostic injection, under the skin. Clinician-published. Studied in: Adults undergoing an organized pituitary test. (source)
- Pituitary response test: IV: 100 mcg once single diagnostic injection, into a vein. Clinician-published. Studied in: Adults undergoing an organized pituitary test. (source)
- LutrePulse: 10 mcg pulses: 10 mcg per pulse every 90 minutes every 90 minutes by pump, under the skin. Studied in a trial. Studied in: Women with primary amenorrhea and hypogonadotropic hypogonadism. (source)
- LutrePulse: 15 mcg pulses: 15 mcg per pulse every 90 minutes every 90 minutes by pump, under the skin. Studied in a trial. Studied in: Women with primary amenorrhea and hypogonadotropic hypogonadism. (source)
- LutrePulse: 20 mcg pulses: 20 mcg per pulse every 90 minutes every 90 minutes by pump, under the skin. Studied in a trial. Studied in: Women with primary amenorrhea and hypogonadotropic hypogonadism. (source)
- Male CHH: response-guided pump: Start 10 mcg per pulse every 90 minutes every 90 minutes by pump, under the skin. Clinician-published. Studied in: Men with confirmed congenital hypogonadotropic hypogonadism. (source)
These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.
Related to Gonadorelin
- Kisspeptin-10: A short-acting experimental peptide that triggers reproductive hormone release.
- hCG: A fertility hormone with limited testosterone add-on evidence and no proven weight-loss benefit.
Sources
- Compounding and the FDA: Questions and Answers, FDA · FDA · 2026
- FDA warning letter 729447: unapproved gonadorelin (2026-06-17), FDA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- FDA CDER alert: compounded-drug recall for lack of sterility assurance (2022-04-26), FDA · 2022
- Gonadorelin 100 micrograms powder for solution for injection, Esteve Pharmaceuticals · 2022
- Expert consensus document: European Consensus Statement on congenital hypogonadotropic hypogonadism--pathogenesis, diagnosis and treatment., Boehm U et al. · Nature reviews. Endocrinology · 2015
- Base de Données Publique des Médicaments, ANSM
- Drugs@FDA: FDA-Approved Drugs, FDA
- Drugs@FDA: FDA-Approved Drugs, FDA
- FD&C Act Provisions that Apply to Human Drug Compounding, FDA · FDA
- PREGNYL- choriogonadotropin alfa kit, Organon
- Product information, Health Canada
- Successful ovulation and pregnancy with pulsatile GnRH pump therapy in a polycystic ovary syndrome (PCOS) patient: a case report., Wang S et al. · Frontiers in endocrinology · 2026
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.